Brintellix vortioxetine: Phase II data

The double-blind, international Phase II CONNECT trial in 602 patients with MDD showed that flexible dosing with once-daily 10-20 mg Brintellix met the primary endpoint of improving cognitive function as measured by DSST score from baseline to week 8 vs. placebo (p<0.05). Brintellix also met the secondary endpoints of improving PDQ (p<0.01) and CGI-I scores (p<0.05) from baseline to week 8 vs. placebo. Additionally, Brintellix significantly improved MADRS (p<0.05) and UPSA (p<0.001) scores vs. placebo. The active comparator duloxetine missed the primary endpoint of improving DSST score from baseline to week 8 vs. placebo, but did significantly improve PDQ, MADRS and CGI-I scores vs. placebo. Data were presented at the International College of Neuropsychopharmacology meeting in Vancouver. ...